Fig. 1From: Low dose DTIC is effective and safe in pretreated patients with well differentiated neuroendocrine tumorsKaplan-Meier survival curves for progression free survival of pancreatic versus non-pancreatic NETs; mPFS: median progression free survival. Overall progression free survival tended to be longer for pancreatic (10 months) than for non pancreatic NETs (6 months) without statistical significance (p = 0.65)Back to article page